These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2111690)

  • 1. [Methods for studying vasodilator agents in Raynaud's phenomenon].
    Planchon B; de Faucal P
    Arch Mal Coeur Vaiss; 1990 Mar; 83 Spec No 2():75-7. PubMed ID: 2111690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Raynaud's phenomenon.
    García-Carrasco M; Jiménez-Hernández M; Escárcega RO; Mendoza-Pinto C; Pardo-Santos R; Levy R; Maldonado CG; Chávez GP; Cervera R
    Autoimmun Rev; 2008 Oct; 8(1):62-8. PubMed ID: 18692160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial.
    Shenoy PD; Kumar S; Jha LK; Choudhary SK; Singh U; Misra R; Agarwal V
    Rheumatology (Oxford); 2010 Dec; 49(12):2420-8. PubMed ID: 20837499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment in Raynaud's disease.
    Hansteen V
    Acta Chir Scand Suppl; 1976; 465():87-91. PubMed ID: 793268
    [No Abstract]   [Full Text] [Related]  

  • 7. [Limitations of cold tests in Raynaud's disease].
    Vayssairat M; Baudot N; Blaison N; Evenou P; Gilard M; Mathieu JF
    J Mal Vasc; 1990; 15(1):82-5. PubMed ID: 2179450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the plethysmographic amplification factor during vasodilator treatment. Healthy subject versus primary Raynaud phenomenon].
    Lasfargues G; Royere D; Perrotin D; Titon JP; Soutif D; Guilmot JL
    J Mal Vasc; 1987; 12(4):319-22. PubMed ID: 3694055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The vasoprostan treatment of patients with Raynaud's syndrome].
    Alekperov RT; Mach ES; Guseva NG
    Ter Arkh; 1997; 69(8):22-3. PubMed ID: 9381386
    [No Abstract]   [Full Text] [Related]  

  • 10. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
    Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
    Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plethysmographic cold test for diagnosis and evaluation of the severity of Raynaud's phenomenon. Validation of the method by factorial analysis of correspondences in 541 patients.
    Pistorius MA; Planchon B; de Faucal P
    Int Angiol; 1994 Mar; 13(1):10-4. PubMed ID: 8077791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil for the treatment of Raynaud's phenomenon.
    Heymann WR
    J Am Acad Dermatol; 2006 Sep; 55(3):501-2. PubMed ID: 16908357
    [No Abstract]   [Full Text] [Related]  

  • 15. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2005 Jun; (13):1546-54. PubMed ID: 16135302
    [No Abstract]   [Full Text] [Related]  

  • 17. Raynaud's phenomenon (primary).
    Pope J
    Clin Evid; 2004 Dec; (12):1725-34. PubMed ID: 15865744
    [No Abstract]   [Full Text] [Related]  

  • 18. [Spasm and Raynaud's phenomenon].
    Fiessinger JN
    Ann Cardiol Angeiol (Paris); 1981; 30(2):91-3. PubMed ID: 7259052
    [No Abstract]   [Full Text] [Related]  

  • 19. Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon.
    DiGiovanni RL; Littlefield JM; Good RG
    J Am Osteopath Assoc; 1995 Oct; 95(10):572. PubMed ID: 8557544
    [No Abstract]   [Full Text] [Related]  

  • 20. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
    Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
    J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.